HDAC6 and Parkinson disease: Inhibitors of deacetylating enzymes such as HDAC6 and Sirt2 have shown promise in restoring tubulin acetylation, improving axonal transport, and exerting neuroprotective effects in models of AD, PD, and HSP.90